Optieum Biotechnologies develops next-generation CAR-T and CAR-NK cell therapies using its proprietary Eumbody System, a platform that empirically optimizes CAR binding domains and scFv constructs for improved T-cell activation, antitumor activity, proliferation, persistence, and reduced antigen escape
Optieum Biotechnologies develops next-generation CAR-T and CAR-NK cell therapies using its proprietary Eumbody System, a platform that empirically optimizes CAR binding domains and scFv constructs for improved T-cell activation, antitumor activity, proliferation, persistence, and reduced antigen escape. Its pipeline includes candidates for solid tumors, hematological malignancies, and autoimmune disorders.
The top three firms on F4's Biotech & Life Sciences investor list.